Objective: To investigate whether intravenous immunoglobulin (IVIG) can improve the chance of livebirth in women with a history of recurrent spontaneous miscarriage (RM). Study design: Randomized, double-blind, placebo-controlled trial.
INTRODUCTION
Of all clinically detected pregnancies approximately 10% end III miscarriage (I).
Recurrent spontaneous miscarriage (RM) is
defined as a series of at least three pregnancy losses, a condition that affects ] % of women who desire a child (2) .RM is classified as either primary (never achieved a live birth) or secondary (normal pregnancy or pregnancy that progressed to at least 26 weeks followed by recurrent abortion) (3) , The frequency of fetal aneuploidy decreases with the number of previous losses (4) , On the Contrary, several studies have reported that the prevalence of immunological disturbances (5) and of particular class I and class II HLA alleles (6, 7) increases with the number of previous pregnancy losses.
A series of autoantibodies (8, 9) and aT-helper type I cytokine bias (10) can be found with increased prevalence in these patients as well.
However, there is so far no definitive diagnostic test that can identify women who have such alloimrnune dysfunction.
In patients negative for autoantibodies, active immunization with allogenic lymphocytes (ALT) from the partner (PLT) or third party donors (DLT) have been used.
ALT increases significantly the chance of
Iivebirth among patients with primary RM with no auto-or alia-antibodies whereas no effect could be detected in patients with secondary RM (11), (12 The presence of an autoimmune rheumatic disease was not a cause of exclusion in this study.
Treatment protocol:
Fifty four women meeting the above mentioned eligibility criteria were recruited for this study.
Patients were instructed to conduct a pregnancy test if menstruation was three days overdue. Once pregnancy was confirmed, the first infusion was given.
After randomization, lVIG and equivalent amounts of saline (placebo) were administered. Losses were considered fetal, if they occurred after the lOth week; embryonic before the lOth week but after documentation of fetal heart rate.
Pregnancies lost before depiction of fetal heart rate were pre-embryonic. 
Checking for hepatitis

Statistical analysis:
Data were expressed as means ± SD.
Paired-t-test and chi-square tests were used to compare results between IVlO and placebo groups.
, RESULTS
From July 2000 to January 2004, 54 women with a history of secondary recurrent miscarriages, who were confirmed to be pregnant before conclusion of the trial were randomized and included in this study. Patients receiving IVIG achieved a LBR of Table II : Pregnancy outcomes in participant groups.
(21/27) 78% compared to (9/27 34% III placebo infused patients, P < 0.01 (Table II) .
All pregnancy losses in IVrG group occurred in the first trimester (one fetal, one pre-embryonic, and two embryonic), whereas four miscarriages in the placebo group, occurred in the second trimester.
Seventy eight percent (7/9) of ACA positive patients assigned to IVIG group achieved a live birth. None of the ACA positive placebo patients had a live birth. Neonatal data did not differ between IVIG and placebo groups; (Table III) Another infant in IVIG group had cleft palate.
In the placebo group only one infant had talipes calcaneocavus.
Tests for antibodies against hepatitis C and HIV remained negative in all patients through and after pregnancy.
Few mild side effects viz; arthralgia, low grade fever, malaise, myalgias and local skin rash were noted in 13 patients receiving IVIG but they were mild in all patients.
Unexpectedly, there was a higher overall live-born female/male gender ratio which was significantly different from the I: I ratio.
LJISCUSSION
The mechanisms that normally prevent a mother from rejecting her semi-allogenic conceptus are unclear.
The majority of recent research has focussed on immunologic causes but appropriate testing and treatment for RM due to immunologic causes is yet to be determined. The results of uncontrolled pilot studies using IVIG were promising with successful pregnancy rate of 82% in women with RM (31~33).
However, The results of the following five randomized controlled trials conducted to evaluate IVrG in RM were conflicting.
At a first glance, these diverging results provided no compelling reason to continue using IVIG in RM.
Nevertheless, the trials of immune therapy are too heterogenous in their inclusion of patients and treatment protocols to reach firm conclusions.
For instance, in this trial 58% (31 / 54) of patients had more than four previous miscarriages.
In the two placebo-controlled trials of the 
